A new once-nightly oral pill called AD109 successfully treated obstructive sleep apnea in a phase 3 clinical trial, with over 40 percent of patients improving their disease severity and 18 percent achieving complete control. The drug, which combines two medications to support throat muscles and prevent airway collapse, showed an apnea-hypoxia index decrease of 44 percent compared to 18 percent in the placebo group.
Topicle Beta
1 comment
A new once-nightly oral pill called AD109 successfully treated obstructive sleep apnea in a phase 3 clinical trial, with over 40 percent of patients improving their disease severity and 18 percent achieving complete control. The drug, which combines two medications to support throat muscles and prevent airway collapse, showed an apnea-hypoxia index decrease of 44 percent compared to 18 percent in the placebo group.